ViiV Healthcare is an independent, global specialist HIV company established in 2009 with commitment to deliver innovative new options for the care and treatment of people living with HIV/AIDS.

Formed through a unique partnership between GSK and Pfizer, the company now combines the HIV expertise of GSK, Pfizer and Shionogi, who joined in 2012 following a long-term collaboration on the joint development of several novel integrase inhibitors.

We are focused on finding new medicines to improve outcomes for people living with HIV and understanding how best to prevent and treat the disease. At ViiV Healthcare our scientists are 100% dedicated to finding new ways to limit the impact of HIV on the 35 million people living with the virus.

Although there have been significant advances in HIV therapy in recent years, until we have a cure we must maintain investment into developing new medicines and remain vigilant over how the virus evolves resistance to treatment.

We know that new medicines will always be needed that are at least as effective as current options and treat patients who have limited options due to the development of resistance. Additionally, new medicines will need to offer improvements in areas such as tolerability, safety, dosing schedules, drug interactions and convenience.

As well as the five investigational medicines we currently have in the clinic, our investment in R&D supports early work to identify new therapeutic options such as antiretroviral drug candidates with novel mechanisms of action and treatment of HIV-related immune dysfunction.

We actively collaborate with other commercial and academic organisations to work towards a cure and also seek new business alliances to ensure we will deliver the innovative HIV treatments of the future.